SecBot SecBot

SAVE Act of 2023

H.R. 6161 Rep. Marcus Molinaro (R-NY-19) In committee
Bill text PDF
  1. Introduced Nov 1
  2. Committee Nov 1
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Nov 1, 2023Next: House vote
1092d ago Nov 1, 2023: Referred to the House Committee on Ways and Means.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 4 filings
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Biotech & Pharma 1
Search all 1 companies, their asks and price moves Subscribe

Summary

This bill amends the Internal Revenue Code to allow expenses for over-the-counter naloxone to count toward the medical expense deduction. Sec. 2, Over-the-counter naloxone included in medical expense deduction: The bill adds 'or naloxone' to the list of items in Section 213(b) of the tax code, alongside insulin, so that amounts paid for over-the-counter naloxone can be considered when calculating the deduction for medical expenses. This change applies to tax years ending after the bill becomes law.

Summary of the bill text as introduced in House (Nov 1, 2023), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.